SBIR/STTR Research Award
Shelf-life Extension for Emergency Medication
Award amount
$1,249,908Program and phase
SBIR · Phase IIAward year
2023Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2023-09-29
- Contract end date
- 2025-06-29
- UEI
- DXRED7S6FVE9
- Solicitation number
- X22.4
- Topic code
- X224-OCSO1
Research abstract
This proposal addresses the Air Force need for personnel to operate independently in far-forward situations, by doubling the shelf-life of oxygen-sensitive medications, starting with epinephrine. Currently, the expiration date on drugs starts with the man
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
- Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
- Extended Utilization of Lifesaving Medications via Autoinjector
- Auto Injector Administration of Ketamine for Critically Injured Airmen
- Life-Saving Mini Auto-Injector to Deliver Epinephrine
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Sustainable, Non-Incineration-based Destruction of Air Force Hazardous Waste Stockpiles : TACFI
- IRONCLAD: Integrated Resilient Operations for Naval Cloud and AI Deployments
- Advancing Trustworthy, High-Performance LLM Applications with Multimodal Data Access
- Armed Overwatch & sUAS Close Air Support Solution for Air Force Special Operations
- Runway Integrity Validation through Soil Moisture Measurements from a small UAS
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense